search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Friso MUM, the activity of a helath supplement during pregnancy and lactation.


- candidate number1577
- NTR NumberNTR366
- ISRCTNISRCTN58176213
- Date ISRCTN created19-dec-2005
- date ISRCTN requested28-okt-2005
- Date Registered NTR12-sep-2005
- Secondary IDsN/A 
- Public TitleFriso MUM, the activity of a helath supplement during pregnancy and lactation.
- Scientific TitleThe effect of high DHA-fish oil and arachidonic acid (AA) suppletion during pregnancy and lactation on LCP status of mother and child and on the neurological development of the baby.
- ACRONYMMUM
- hypothesisDHA and AA during pregnancy shall lead to a better neurological development of the baby and possibly to better mood, cognitive functioning and sleeping rhythm of the mother.
- Healt Condition(s) or Problem(s) studiedDevelopmental disorder
- Inclusion criteria1. Apparently healthy pregnant women;
2. Para 0 or 1;
3. Inclusion should take place prior to the 16th week of pregnancy.
- Exclusion criteria1. Hyperemesis Gravidarum
2. Vegetarian of Vegan;
3. Pregnant with twins;
4. Diabetes Mellitus type 1;
5. Usage of helath supplements with fatty acids, tryptophan or melatonin.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-nov-2004
- planned closingdate1-okt-2007
- Target number of participants300
- InterventionsEverybody recieves a multivitamin supplement (desgined for pregnant women).
Next to that we compare placebo vs DHA vs DHA/AA.
- Primary outcomeNeurological Development of the baby (Neurological Optimality Score and General Movements).
- Secondary outcome1. Mood, cognitive functioning and sleeping rhythm of the mother;
2. LCP status in red blood cells of mother (16th and 36th week) and child (12 weeks after birth), umbilical cord, breast milk (2 and 12 weeks after birth).
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESDrs. Saskia A. Goor, van
- CONTACT for SCIENTIFIC QUERIESProf. Dr. F.A.J. Muskiet
- Sponsor/Initiator Friesland Foods
- Funding
(Source(s) of Monetary or Material Support)
[default]
- PublicationsN/A
- Brief summaryHelathy pregnant women are included prior to the 16th week of pregnancy and are followed till 12 weeks postpartum. During the whole period they have to take the supplement provided and the effect on nuerological development is judged.
- Main changes (audit trail)
- RECORD12-sep-2005 - 13-jan-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl